Drug Type Small molecule drug |
Synonyms E 7107, E7107 |
Target |
Action antagonists |
Mechanism SF3B antagonists(Splicing factor 3B antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseSuspendedPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC40H66N2O9 |
InChIKeyMNOMBFWMICHMKG-MGYWSNOQSA-N |
CAS Registry630100-90-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 1 | Netherlands | 01 May 2007 | |
Solid tumor | Phase 1 | Spain | 01 May 2007 |
Phase 1 | - | qziwcylnye(ofuvxditah) = Vision loss was experienced by two patients at Cycles 2 and 7, each patient receiving 3.2 mg/m(2) and 4.3 mg/m(2), respectively vdfqlyvmmr (mybiqwavsg ) | - | 01 Jun 2014 | |||
Phase 1 | 36 | capmbwznuh(jjzvqeodaw) = iopsayxbvb gflpibxnzq (zxwjqavpkf ) | - | 20 May 2009 |